SEL1L: molecular gatekeeper of the endoplasmic reticulum quality control network
Experimental Biology and Medicine · 30.10.2026 · 251
DOI: 10.3389/ebm.2026.11350 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Experimental Biology and Medicine, online erschienen am 30.10.2026. Verfasst von Zhenxuan Shen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, Guangxi, China. Hauptthemen laut MEDLINE: Endoplasmic Reticulum, Endoplasmic Reticulum-Associated Degradation, Proteins. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
SEL1L (suppressor/enhancer of lin-12-like) is an endoplasmic reticulum (ER) transmembrane protein that serves as a key regulatory molecule in the endoplasmic reticulum-associated degradation (ERAD) pathway, playing a central role in maintaining intracellular protein homeostasis. This paper provides a systematic review of SEL1L’s structural characteristics, the molecular mechanisms by which it forms a functional complex with the E3 ubiquitin ligase HMG-CoA reductase degradation protein 1 (HRD1, encoded by SYVN1 ) to synergistically execute ERAD, and its pathophysiological significance in the onset and progression of various diseases. Research indicates that SEL1L dysfunction is closely associated with pathogenic protein aggregation in neurodegenerative diseases (e.g., Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis), protein homeostasis imbalances during tumorigenesis, cellular metabolic dysregulation in metabolic disorders (e.g., diabetes, lipid metabolism disorders), and immune system dysfunction. Furthermore, the expression levels or variants of SEL1L exhibit specific alterations across different tumor tissues, suggesting its potential as a disease biomarker and therapeutic target. This paper aims to synthesize existing research, elucidate the ‘gatekeeper’ role of SEL1L in multiple physiological and pathological processes, and explore the prospects for developing novel therapeutic strategies by targeting the SEL1L-HRD1 complex and related pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, Guangxi, China.
- Department of Neurology, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
- Guangxi Medical and Health Key Cultivation Discipline Construction Project, Guilin, Guangxi, China.
- Institute of Pathogenic Biology, Guilin Medical University, Guilin, Guangxi, China.
Zitieren
APA
Shen, Z., Niu, Y., Chen, H., Pan, M., Yang, F., Li, M., Zhang, C., Zhou, Y., & Yan, J. (2026). SEL1L: molecular gatekeeper of the endoplasmic reticulum quality control network. Experimental Biology and Medicine, 251. https://doi.org/10.3389/ebm.2026.11350
Vancouver
Shen Z, Niu Y, Chen H, Pan M, Yang F, Li M, et al. SEL1L: molecular gatekeeper of the endoplasmic reticulum quality control network. Experimental Biology and Medicine. 2026;251. doi:10.3389/ebm.2026.11350
BibTeX
@article{Shen2026,
author = {Shen, Zhenxuan and Niu, Yiting and Chen, Hedong and Pan, Meikun and Yang, Fan and Li, Meiying and Zhang, Chong and Zhou, Yali and Yan, Jianguo},
title = {SEL1L: molecular gatekeeper of the endoplasmic reticulum quality control network},
journal = {Experimental Biology and Medicine},
year = {2026},
volume = {251},
doi = {10.3389/ebm.2026.11350}
}
EUVIMED